Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859 · see citing works

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · see citing works

Protein aggregation and neurodegenerative disease

Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · see citing works

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055 · see citing works

Neuropathological Classification of Huntingtonʼs Disease

Vonsattel, J., Myers, R. H., STEVENS, T. J., Ferrante, R. J., Bird, E. D., & Richardson, E. P. (1985) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,598 · see citing works

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,071 · see citing works

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,056 · see citing works

A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window

Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040 · see citing works

Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline

Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · see citing works

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease

Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · see citing works

Selective Sparing of a Class of Striatal Neurons in Huntington's Disease

Ferrante, R. J., Kowall, N. W., Beal, M. F., Richardson, E. P., Bird, E. D., & Martin, J. B. (1985) · Science · doi:10.1126/science.2931802 · Cited by 757 · see citing works

Coenzyme Q ₁₀ administration increases brain mitochondrial concentrations and exerts neuroprotective effects

Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557 · see citing works

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

Chen, D., Endres, R. L., Erickson, C. A., Weis, K. F., McGregor, M. W., Kawaoka, Y., & Payne, L. G. (2000) · Nature Medicine · doi:10.1038/80538 · Cited by 547 · see citing works

Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain

Sapp, E., Kegel, K. B., D, N. A. M., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J., & DiFiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 537 · see citing works

Transcriptional abnormalities in Huntington disease

Sugars, K. L., & Rubinsztein, D. C. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00074-x · Cited by 529 · see citing works

The Promise of Minocycline in Neurology

Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518 · see citing works

Targeting leukocyte MMPs and transmigration

Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C. A., & Yong, V. W. (2002) · Brain · doi:10.1093/brain/awf133 · Cited by 427 · see citing works

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E. F., Ferrante, R. J., Kristal, B. S., & Friedlander, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832501100 · Cited by 407 · see citing works

Transcriptional dysregulation in Huntington’s disease

Cha, J.-H. J. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01609-x · Cited by 399 · see citing works

Therapeutic Effects of Coenzyme Q₁₀and Remacemide in Transgenic Mouse Models of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391 · see citing works

Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury

Teng, Y. D., Choi, H., Onario, R. C., Zhu, S., Desilets, F. C., Lan, S., Woodard, E. J., Snyder, E. Y., Eichler, M. E., & Friedlander, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306239101 · Cited by 335 · see citing works

A randomized, placebo-controlled trial of coenzyme Q ₁₀ and remacemide in Huntington’s disease

The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312 · see citing works

Weight loss in early stage of Huntington’s disease

Djoussé, L., Knowlton, B. A., Cupples, L. A., Marder, K. S., Shoulson, I., & Myers, R. H. (2002) · Neurology · doi:10.1212/01.wnl.0000031791.10922.cf · Cited by 284 · see citing works

Minocycline as a Neuroprotective Agent

Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 280 · see citing works

Movement disorders : neurologic principles and practice

Watts, R. L., & Koller, W. C. (1997) · McGraw-Hill, Health Professions Division eBooks · Cited by 256 · see citing works

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice

Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Signore, S. J. D., Guélin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 246 · see citing works

Movement Disorders: Neurologic Principles and Practice

O’Suilleabhain, P. E. (1997) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63690-2 · Cited by 227 · see citing works

Experimental therapeutics in transgenic mouse models of Huntington's disease

Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 224 · see citing works

Neuroprotection by tetracyclines

Domercq, M., & Matute, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.001 · Cited by 205 · see citing works

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173 · see citing works

Mitochondrial encephalomyopathy (MELAS): Pathological study and successful therapy with coenzyme Q10 and idebenone

Ihara, Y., Namba, R., Kuroda, S., SATO, T. A., & Shirabe, T. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90112-3 · Cited by 161 · see citing works

Minocycline prevents glutamate‐induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways

Pi, R., Li, W., Lee, N. T. K., Chan, H. H. N., Pu, Y., Chan, L. N., Sucher, N. J., Chang, D. C., Li, M., & Han, Y. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02796.x · Cited by 145 · see citing works

Minocycline prevents cholinergic loss in a mouse model of Down's syndrome

Hunter, C. L., Bachman, D., & Granholm, A. (2004) · Annals of Neurology · doi:10.1002/ana.20250 · Cited by 120 · see citing works

Depletion of wild‐type huntingtin in mouse models of neurologic diseases

Zhang, Y., Li, M., Drozda, M., Chen, M., Ren, S., Sanchez, R. O. M., Leavitt, B. R., Cattaneo, E. F., Ferrante, R. J., Hayden, M. R., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01980.x · Cited by 120 · see citing works

Minocycline in Huntington's disease: A pilot study

Thomas, M., Ashizawa, T., & Jankovic, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111 · see citing works

Translating therapies for Huntington’s disease from genetic animal models to clinical trials

Hersch, S. M., & Ferrante, R. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.3.298 · Cited by 75 · see citing works

Therapeutic Effects of Coenzyme Q10 in Neurodegenerative Diseases

Beal, M. F. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82026-3 · Cited by 54 · see citing works

Minocycline is protective in a mouse model of Huntington's disease

Hersch, S. M., Fink, K., Vonsattel, J. P., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.21891 · Cited by 42 · see citing works

Emerging chemotherapeutic strategies for Huntington’s disease

Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 29 · see citing works

Coenzyme Q Cytoprotective Mechanisms

Chan, T. S., Wilson, J. X., & O'Brien, P. J. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82006-8 · Cited by 16 · see citing works

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · see citing works

Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities

Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480 · see citing works

Minocycline and Neurodegenerative Diseases

Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447 · see citing works

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 416 · see citing works

N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease

FAN, M., & Raymond, L. A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.003 · Cited by 410 · see citing works

Altered Lipid Metabolism in Brain Injury and Disorders

Rao, A. M., & Hatcher, J. F. (2008) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-8831-5_9 · Cited by 404 · see citing works

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works

Mitochondria: A therapeutic target in neurodegeneration

Moreira, P. I., Zhu, X., Wang, X., Lee, H., Nunomura, A., Petersen, R. B., Perry, G. L., & Smith, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.007 · Cited by 286 · see citing works

Prospects for Minocycline Neuroprotection

Plane, J. M., Shen, Y., Pleasure, D., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276 · see citing works

Role Of Lipids In Brain Injury And Diseases

Rao, A. M., & Hatcher, J. F. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.403 · Cited by 270 · see citing works

Animal Models of Huntington's Disease

Ramaswamy, S., McBride, J. L., & Kordower, J. H. (2007) · ILAR Journal · doi:10.1093/ilar.48.4.356 · Cited by 234 · see citing works

Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease

Estrada‐Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.11.011 · Cited by 213 · see citing works

Coenzyme Q10 effects in neurodegenerative disease

Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 188 · see citing works

The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity

Wang, X., Sirianni, A. C., Pei, Z., Cormier, K., Smith, K., Jiang, J., Zhou, S., Wang, H., Zhao, R., Yano, H., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3059-11.2011 · Cited by 186 · see citing works

Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease

Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F. S., & Fusco, F. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013417 · Cited by 184 · see citing works

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies

Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178 · see citing works

Neuroinflammation in Huntington’s disease

Möller, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0430-7 · Cited by 174 · see citing works

Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 167 · see citing works

Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3‐Nitropropionic Acid‐Induced Rat Model of Huntington's Disease

Chakraborty, J., Singh, R. P., Dutta, D., Naskar, A., Rajamma, U., & Mohanakumar, K. P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12189 · Cited by 145 · see citing works

Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders

Mancuso, M., Orsucci, D., Volpi, L., Calsolaro, V., Siciliano, G., Spinelli, A., Correale, C., Szabó, H., & Montorsi, M. (2009) · Current Drug Targets · doi:10.2174/138945010790031018 · Cited by 139 · see citing works

Lipids: An insight into the neurodegenerative disorders

Shamim, A., Mahmood, T., Ahsan, F., Kumar, A., & Bagga, P. (2018) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2018.05.001 · Cited by 126 · see citing works

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139 · see citing works

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease

Cho, S., Benraiss, A., Chmielnicki, E., Samdani, A. F., Economides, A. N., & Goldman, S. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31778 · Cited by 138 · see citing works

Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease

Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136 · see citing works

Neurotoxicity with Antimicrobials in the Elderly: A Review

Mattappallil, A., & Mergenhagen, K. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.020 · Cited by 125 · see citing works

Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease

Wang, X., Zhu, S., Pei, Z., Drozda, M., Stavrovskaya, I. G., Signore, S. J. D., Cormier, K., Shimony, E. M., Wang, H., Ferrante, R. J., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1867-08.2008 · Cited by 120 · see citing works

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease

DeMarch, Z., Giampà, C., Patassini, S., Bernardi, G., & Fusco, F. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.02.010 · Cited by 117 · see citing works

Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

Giri, P. M., Banerjee, A., Ghosal, A., & Layek, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073995 · Cited by 123 · see citing works

The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?

Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101 · see citing works

A futility study of minocycline in Huntington's disease

Cudkowicz, M., & The Huntington Study Group DOMINO Investigators (2010) · Movement Disorders · doi:10.1002/mds.23236 · Cited by 97 · see citing works

Inflammation in transgenic mouse models of neurodegenerative disorders

Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97 · see citing works

Minocycline in neurodegenerative and psychiatric diseases: An update

Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 95 · see citing works

The Therapeutic Role of Minocycline in Parkinson’s Disease

Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93 · see citing works

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II

Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 82 · see citing works

Animal models of Huntington's disease for translation to the clinic: Best practices

Menalled, L., & Brunner, D. (2014) · Movement Disorders · doi:10.1002/mds.26006 · Cited by 79 · see citing works

Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.

Ryu, J. K., Choi, H. B., & McLarnon, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.043 · Cited by 83 · see citing works

Coenzyme Q10 a mitochondrial restorer for various brain disorders

Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 77 · see citing works

Redox Control of the Ubiquitin-Proteasome System: From Molecular Mechanisms to Functional Significance

Kriegenburg, F., Poulsen, E. G., Koch, A., Krüger, E., & Hartmann‐Petersen, R. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3590 · Cited by 75 · see citing works

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice

Simmons, D. A., Mehta, R. A., Lauterborn, J. C., Gall, C. M., & LYNCH, G. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.015 · Cited by 75 · see citing works

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Alpaugh, M., Galleguillos, D., Forero, J. P., Morales, L. C., Lackey, S. W. K., Kar, P., Pardo, A. D., Holt, A., Kerr, B. J., Todd, K. G., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707763 · Cited by 73 · see citing works

Is it possible to improve neurodevelopmental abnormalities in Down syndrome?

Bartesaghi, R., Guidi, S., & Ciani, E. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.037 · Cited by 74 · see citing works

Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics

Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70 · see citing works

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington's Disease Shows No Benefit from CoQ10 or Minocycline

Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 70 · see citing works

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding

Noble, W. J., Garwood, C. J., & Hanger, D. P. (2009) · Prion · doi:10.4161/pri.3.2.8820 · Cited by 67 · see citing works

The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease

Gil‐Mohapel, J., & Rego, A. C. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.001 · Cited by 63 · see citing works

Targeting mitochondrial dysfunction in neurodegenerative disease: Part I

Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652489 · Cited by 63 · see citing works

The role of immunity in Huntington's disease

Soulet, D., & Cicchetti, F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.28 · Cited by 62 · see citing works

Coenzyme Q10 effects in neurological diseases

Rauchová, H. (2021) · Physiological Research · doi:10.33549/physiolres.934712 · Cited by 63 · see citing works

The microbiota–gut–brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets

Ekwudo, M. N., Gubert, C., & Hannan, A. J. (2024) · FEBS Journal · doi:10.1111/febs.17102 · Cited by 59 · see citing works

Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies

Ramaswamy, S., Shannon, K. M., & Kordower, J. H. (2007) · Cell Transplantation · doi:10.3727/000000007783464687 · Cited by 59 · see citing works

Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease

Paldino, E., Balducci, C., Vitola, P. L., Artioli, L., D’Angelo, V., Giampà, C., Artuso, V., Forloni, G., & Fusco, F. R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01847-8 · Cited by 56 · see citing works

Nortriptyline delays disease onset in models of chronic neurodegeneration

Wang, H., Guan, Y., Wang, X., Smith, K., Cormier, K., Zhu, S., Stavrovskaya, I. G., Huo, C., Ferrante, R. J., Kristal, B. S., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05663.x · Cited by 53 · see citing works

Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke

Tarawneh, R. M., & Galvin, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.12.003 · Cited by 53 · see citing works

Targeting Glial Cells to Elucidate the Pathogenesis of Huntington’s Disease

Hsiao, H., & Chern, Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8097-5 · Cited by 50 · see citing works

Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease

El–Akabawy, G., Rattray, I., Johansson, S., Gale, R. P., Bates, G. P., & Modo, M. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-97 · Cited by 47 · see citing works

Coenzyme Q10 and Neurological Diseases

Mancuso, M., Orsucci, D., Calsolaro, V., Choub, A., & Siciliano, G. (2009) · Pharmaceuticals · doi:10.3390/ph203134 · Cited by 46 · see citing works

Microglial Inhibitory Mechanism of Coenzyme Q10 Against Aβ (1-42) Induced Cognitive Dysfunctions: Possible Behavioral, Biochemical, Cellular, and Histopathological Alterations

Singh, A., & Kumar, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00268 · Cited by 45 · see citing works

Immunotherapies in Huntington's disease and α-Synucleinopathies

Fatoba, O., Ohtake, Y., Itokazu, T., & Yamashita, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00337 · Cited by 43 · see citing works

Huntington's disease: progress and potential in the field

Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39 · see citing works

Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38 · see citing works

Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease

Hickey, M. A., Zhu, C., Medvedeva, V. P., Franich, N. R., Levine, M. S., & Chesselet, M. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.10.007 · Cited by 35 · see citing works

Impairment of mitochondrial function by minocycline

Kupsch, K., Hertel, S., Kreutzmann, P., Wolf, G. L., Wallesch, C.-W., Siemen, D., & Schönfeld, P. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.06904.x · Cited by 34 · see citing works

Emerging drug therapies in Huntington's disease

Mason, S., & Barker, R. A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902918299 · Cited by 34 · see citing works

Are immunotherapies for Huntington’s disease a realistic option?

Denis, H. L., Lauruol, F., & Cicchetti, F. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0021-9 · Cited by 32 · see citing works

Minocycline attenuates depressive-like behaviors in mice treated with the low dose of intracerebroventricular streptozotocin; the role of mitochondrial function and neuroinflammation

Mozafari, H., Amiri, S., Mehr, S. E., Momeny, M., Amini-Khoei, H., Bijani, S., & Hosseini, M.-J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05696-w · Cited by 32 · see citing works

Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature

Mason, S., & Barker, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109630 · Cited by 30 · see citing works

Inflammation and Huntington’s disease – a neglected therapeutic target?

Field, S., Curle, A. J., & Barker, R. A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2348738 · Cited by 28 · see citing works

Metalloproteinases and their inhibitors in neurological disease

Lopez-Navarro, E. R., & Gutierrez, J. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02188-x · Cited by 28 · see citing works

Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging

Aggarwal, M., Duan, W., Hou, Z., Rakesh, N., Peng, Q., Ross, C. A., Miller, M. I., Mori, S., & Zhang, J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.141 · Cited by 28 · see citing works

Environmental stimulation in Huntington disease patients and animal models

Novati, A., Nguyen, H. P., & Schulze-Hentrich, J. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105725 · Cited by 26 · see citing works

Ubisol-Q10, a Nanomicellar and Water-Dispersible Formulation of Coenzyme-Q10 as a Potential Treatment for Alzheimer’s and Parkinson’s Disease

Wear, D., Vegh, C., Sandhu, J. K., Sikorska, M., Cohen, J. S., & Pandey, S. (2021) · Antioxidants · doi:10.3390/antiox10050764 · Cited by 25 · see citing works

Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases

Ebrahimi, A., Kamyab, A., Hosseini, S., Ebrahimi, S., & Ashkani‐Esfahani, S. (2023) · Biochemistry Research International · doi:10.1155/2023/5510874 · Cited by 29 · see citing works

Lack of Minocycline Efficiency in Genetic Models of Huntington's Disease

Mievis, S., Levivier, M., Communi, D., Vassart, G., Brotchi, J., Ledent, C. A., & Blum, D. L. (2006) · NeuroMolecular Medicine · doi:10.1385/nmm:9:1:47 · Cited by 24 · see citing works

Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease

Bortvedt, S. F., McLear, J. A., Messer, A. C., Ahern‐Rindell, A. J., & Wolfgang, W. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.007 · Cited by 24 · see citing works

RNAi Therapy for Neurodegenerative Diseases

Boudreau, R. L., & Davidson, B. L. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75003-7 · Cited by 24 · see citing works

Controlled and Impaired Mitochondrial Quality in Neurons: Molecular Physiology and Prospective Pharmacology

Matić, I., Strobbe, D., Frison, M., & Campanella, M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.021 · Cited by 23 · see citing works

Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice

Cipriani, S., Bizzoco, E., Gianfriddo, M., Melani, A., Vannucchi, M. G., & Pedata, F. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.05.015 · Cited by 22 · see citing works

Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts

Esteves, S., Duarte‐Silva, S., & Maciel, P. (2016) · Medicinal Research Reviews · doi:10.1002/med.21425 · Cited by 20 · see citing works

Experimental Models of HD and Reflection on Therapeutic Strategies

Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 19 · see citing works

Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities

Stock, M. L., Fiedler, K. J., Acharya, S., Lange, J. K., Mlynarczyk, G. S. A., Anderson, S. J., Schmidt-McCormack, G. R., Kanuri, S. H., Kondru, N. C., Brewer, M. T., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.059 · Cited by 19 · see citing works

Mitochondrial homeostasis regulation: A promising therapeutic target for Parkinson's disease

Yao, M., Dang, T., Wang, H., Zhu, X., & Chen, Q. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114811 · Cited by 15 · see citing works

Specific combinations of ion channel inhibitors reduce excessive Ca2+ influx as a consequence of oxidative stress and increase neuronal and glial cell viability in vitro

Doig, R. O., Bartlett, C. A., Smith, N. M., Hodgetts, S. I., Dunlop, S. A., Hool, L. C., & Fitzgerald, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.10.005 · Cited by 15 · see citing works

Nanotechnology‐Enabled Delivery Systems for Food Functionalization and Fortification

Tiwari, R., & Takhistov, P. (2012) · doi:10.1002/9781118229347.ch5 · Cited by 14 · see citing works

Yeast as a model for the identification of novel survival-promoting compounds applicable to treat degenerative diseases

Verbandt, S., Cammue, B. P. A., & Thevissen, K. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.06.003 · Cited by 13 · see citing works

Huntington’s Disease Pathogenesis: Mechanisms and Pathways

Spada, A. R. L., Weydt, P., & Pineda, V. V. (2011) · Europe PMC (PubMed Central) · Cited by 13 · see citing works

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease

Lopes‐Ramos, C. M., Pereira, T. C., Dogini, D. B., Gilioli, R., & Lopes‐Cendes, Í. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165805 · Cited by 13 · see citing works

Huntington Disease

Wagner, L. A., Menalled, L., Goumeniouk, A. D., Brunner, D., & Leavitt, B. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00018-7 · Cited by 12 · see citing works

Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease

Brett, A., Rosenstock, T. R., & Rego, A. C. (2014) · Current Drug Targets · doi:10.2174/1389450114666131124140704 · Cited by 11 · see citing works

Basal ganglia disorders

Melnick, M. E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-07586-2.00029-7 · Cited by 13 · see citing works

AAV-Dominant Negative Tumor Necrosis Factor (DN-TNF) Gene Transfer to the Striatum Does Not Rescue Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease

Alto, L. T., Chen, X., Ruhn, K. A., Treviño, I., & Tansey, M. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096544 · Cited by 10 · see citing works

Neuroprotective effects of flavonoids

Taghizadieh, M., Modiri, N., Salmaninejad, A., Khayami, R., Taheri, F., Moghoofei, M., Khatami, A., Azhdari, S., Bayat, M., Samadi-khouzani, A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824467-8.00016-4 · Cited by 8 · see citing works

Neuroprotective potential of coenzyme Q10

Tripathi, S., Mishra, R., & Singh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00057-9 · Cited by 8 · see citing works

Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's disease

Rolfes, S., Munro, D. A. D., Lyras, E. M., Matute, E., Ouk, K., Harms, C., Böttcher, C., & Priller, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105024 · Cited by 8 · see citing works

Estrés oxidativo y neurodegeneración: ¿causa o consecuencia?

Angoa‐Pérez, M., & Rivas-Arancibia, S. (2007) · Archivos de Neurociencias · Cited by 7 · see citing works

Neuroinflammation in Huntington’s Disease

Staal, R. G. W., & Möller, T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_10 · Cited by 6 · see citing works

Neuroinflammation in Alzheimer's, Parkinson's and Huntington's Diseases

Sastre, M., Katsouri, L., Birch, A. M., Renziehausen, A., Dexter, D. T., Crichton, R. R., & Ward, R. J. (2014) · Wiley eBooks · doi:10.1002/9781118406557.ch6 · Cited by 6 · see citing works

Preclinical and Clinical Role of Coenzyme Q10 Supplementation in Various Pathological States

Kumar, R., Khan, M. I., Prasad, M., Kumar, S. R., & Kumar, S. S. (2022) · Drug Research · doi:10.1055/a-1835-1738 · Cited by 5 · see citing works

Neurotoxicity induced by lipid metabolism–associated endogenous toxicants

Mahalakshmi, K., Duraisamy, P., Sangeetha, R., Martin, L. C., Manikandan, B., & Manikandan, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00079-8 · Cited by 4 · see citing works

Disease-Modification in Huntington’s Disease: Moving Away from a Single-Target Approach

Jensen, M. P., & Barker, R. A. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-180320 · Cited by 4 · see citing works

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington's Disease Shows No Benefit from CoQ10 or Minocycline

Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 70 · see citing works

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington’s Disease Shows No Benefit from

Minocycline, C. O., Menalled, L., Patry, M., Ragl, N., Lowden, P. A. S., Goodman, J., Zahasky, B., Park, L., Leeds, J., Howl, D., et al. (2010)

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151 · see citing works

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127 · see citing works

Therapeutic Effects of Coenzyme Q₁₀and Remacemide in Transgenic Mouse Models of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391 · see citing works